Theregen, Inc.

Author: Siani-Rose, Michael

Source: Regenerative Medicine, Volume 1, Number 6, November 2006 , pp. 841-846(6)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Theregen, Inc. is a regenerative medicine company based in San Francisco, California, USA, that develops cell-based therapies for patients with cardiovascular and vascular disease. The company is conducting a Phase I human clinical safety trial at two US sites for its lead product, Anginera^TM, a cell-based epicardial patch therapy. Anginera is designed to promote blood vessel growth in damaged cardiac tissue, stimulate wound healing and, potentially, to restore cardiac function in patients with heart failure.

Keywords: Anginera™™; angiogenesis; CABG; cardiac patch or heart patch; diffuse small vessel disease; heart failure

Document Type: Research article

DOI: http://dx.doi.org/10.2217/17460751.1.6.841

Affiliations: 1: Theregen, Inc., 225 Bush Street, 16th Floor San Francisco, CA 94104, USA., Email: msianirose@theregencompany.com

Publication date: 2006-11-01

More about this publication?

Regenerative Medicine provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats vital to an increasingly time-constrained community.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites